26 Jun 2019

ABBVIE ACQUIRING ALLERGAN AS HEDGE AGAINST EXPIRATION OF HUMIRA PATENT

As a hedge against the 2023 expiration of its U.S. patents that protect its blockbuster drug, Humira, AbbVie Inc. will acquire Dublin, Ireland-based Allergan for $63 billion in cash and stock.     Humira sales account for more than 60 percent of AbbVie’s revenue, but biosimilar drugs approved in Europe

0
12 Jun 2019

VICI VENOUS STENT: FDA OKs VICI Venous Stent to treat Iliofemoral obstructive disease

    The U.S Food and Drug Administration has approved Boston Scientific’s VICI Venous Stent System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies.

0
12 Jun 2019

VECLOSE EXTENSION STUDY: Five-year outcomes prove durability, safety, efficacy of VenaSeal Closure System

    By Larry Storer Five-year results from the 2019 VeClose Extension Study of the Medtronic VenaSeal Closure System demonstrate that the treatment modality is consistent, durable and safe for permanently closing veins in patients with venous reflux disease. When compared with Medtronic Radiofrequency Ablation, VenaSeal continued to show “non-inferiority”

0
12 Jun 2019

MERZ REGAINS SOLE DISTRIBUTION OF ASCLERA FROM ANGIODYNAMICS

  Merz North America Inc. has regained exclusive distribution of Asclera (polidocanol) Injection in the United States to all healthcare practitioners and phlebologists treating varicose veins. Also effective April 8, AngioDynamics Inc. is no longer an authorized distributor of Asclera. All HCPs will now be able to purchase Asclera directly

0
11 Jun 2019

WHEN IT COMES TO OUR HEALTH – EVERY SECOND COUNTS

By Seema Verma Healthcare: American’s favorite debate topic.  While there is much to debate, we can all agree that the patient-provider relationship has been strained by unnecessary regulations and reporting requirements. Too much regulation has had the unintentional result of putting the government first and the patient second.  Time spent

0
07 Jun 2019

SOCIAL SECURITY ERROR JEOPARDIZES MEDICARE COVERAGE FOR 250,000 SENIORS

By Susan Jaffe   At least a quarter of a million Medicare beneficiaries may receive bills for as many as five months of premiums they thought they already paid. But they shouldn’t toss the letter in the garbage. It’s not a scam or a mistake.   Because of what the

0
07 Jun 2019

A LARGE EMPLOYER ‘FRAMES’ THE ‘MEDICARE FOR ALL’ DEBATE

  By Phil Galewitz   Walk into a big-box retailer such as Walmart or Michaels and you’re likely to see MCS Industries’ picture frames, decorative mirrors or kitschy wall décor. Adjacent to a dairy farm a few miles west of downtown Easton, MCS is the nation’s largest maker of such household

0
05 Jun 2019

CVS still defending the Aetna merger deal 

CVS Health is making the case for its merger with Aetna to two very different audiences beginning June 3. CVS held its annual investor day and issued a long-term strategic plan to “accelerate growth” ahead of the day’s proceedings, aimed at nervous investors concerned about its recent financial performance post-merger. CVS warned that it

0
24 May 2019

USE OF BUPRENORPHINE TO TREAT OPIOID ADDICTION PROLIFERATES IN CALIFORNIA

By Harriet Blair Rowan Buprenorphine, a relative newcomer in the treatment of opioid addiction, is growing in popularity among California doctors as regulatory changes, physician training and other initiatives make the medication more widely accessible. The rate of Medi-Cal enrollees who received buprenorphine nearly quadrupled from the end of 2014 to

0
24 May 2019

ANALYSIS: A HEALTH CARE OVERHAUL COULD KILL 2 MILLION JOBS, AND THAT’S OK

By Elisabeth Rosenthal As calls for radical health reform grow louder, many on the right, in the center and in the healthcare industry are arguing that proposals like “Medicare for All” would cause economic ruin, decimating a sector that represents nearly 20% of our economy. While exploring a presidential run,

0